NFE2L2 and cancer: Furthermore, since it has been shown that ferroptosis inducers capable of activating Nrf2 pathway promote cellular adaptation and survival and render cancer cells less sensitive to ferroptosis induction themselves [87,88,89], it could be thought that they cannot be considered good candidates for anticancer therapy.